Pfizer said its full-year profit should benefit from cost cuts across its research and manufacturing operations after posting higher-than-expected second-quarter earnings on Tuesday. CEO Albert Bourla also said the company has been in active discussions with members of the U.

U.S. drugmaker Pfizer on Tuesday raised its full-year profit forecast on strong demand for its heart disease drug, Vyndaqel, and blood thinner, Eliquis, after its second-quarter results benefited from a weaker dollar.

Last December, the company raised its quarterly payout for the 16th consecutive year. The dividend yield investors could receive from Pfizer stock has risen from about 3% in early 2022 to 7% when the market closed on Aug.

Pfizer Inc.’s stock was rallying Tuesday after the drug giant lifted its 2025 adjusted profit estimate, on the heels of a 10% jump in second-quarter revenue on strength in its Vyndaqel heart medication and its COVID-19 drugs.

Pharmaceutical major recorded a revenue jump to $14.65 billion, exceeding the market expectations. The company also raised its profit forecast for 2025 over cost cuts.

Pfizer stock jumped Tuesday after the S&P 500 pharma titan beat second-quarter expectations on the back of solid cost-cutting measures.